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The continuous consumption of high-fat high-carbohydrate (HFHC) diet with sedentary 
lifestyle has been shown to cause type 2 diabetes (T2D) in human beings. However, human 
beings suffer from pre-diabetes for a long period before onset of T2D. It has also been shown 
that type 2 diabetic patients have suppressed immune system due to dysregulated innate 
immunity. However, it’s still unclear whether the immune activation occurs at a pre-diabetic 
stage. A rat model has been discovered that mimics the western or high-fat high-carbohydrates 
consumed by humans with sedentary lifestyle for detailed research based on the pre-diabetic 
stage that precedes T2D. In this study, the aim is to characterise if there are changes in immune 
cell concentration during the progression of pre-diabetes stage and evaluate if immune 
activation occurs at pre-diabetes stage. The experimental work described in this dissertation 
was conducted at University of Kwa-Zulu natal, Westville campus, Durban, South Africa. Lipid 
profile samples we analysed at Global Clinical and Viral laboratory at Amanzimtoti, Durban, 
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The current dissertation is presented in manuscript format, consisting of 6 sections viz. chapter 
1: introduction /literature review, chapter 2: prologue, abstract and manuscript 1, chapter 3: 
synthesis and appendices. Chapter 1 lay a foundation of the literature and the information that 
has been discovered in order to link the area of interest of the study and cover a gab that is a 
debatable issue. Chapter 2 contains a prologue of the research of interest, the abstract of the 
study and the manuscript of the research that has covered a gab of the immune cell concentration 
changes during progression of pre-diabetes to type 2 diabetes and upregulation of inflammatory 
markers such as IL-6, TNF-α, CRP, fibrinogen, P-selectin and CD40L at pre-diabetes stage. 
This is the work authored by A Khathi, P.S Ngubane and N.C Mzimela. This work has been 
published in Autoimmunity (Impact factor 2.648). Chapter 3 discusses the synthesis of the 














T2D has been discovered to be preceded by a long-lasting condition known as prediabetes. The 
primary cause of prediabetes and T2D has also been shown to be continuous consumption of 
unhealthy diets and living a sedentary lifestyle. Type 2 diabetic patients have been discovered 
to have a supressed immune system, but it is still debatable whether immune activation begins 
at the pre-diabetes stage or during overt T2D. According to literature, T2D is a result of elevated 
levels of glucose known as hyperglycaemia caused by a condition called insulin resistance. 
Additionally, T2D has also been shown to be characterised by increased levels of triglycerides, 
low density lipoproteins (LDL) and decreased levels of high-density lipoproteins (HDL). 
Insulin resistance then causes metabolic and signalling pathways such as oxidative stress, 
activation of PKC pathway, formation of advanced glycation end products (AGEs) and shunting 
of polyol pathway which trigger metabolic inflammation resulting in a dysregulated innate 
immunity. Dysregulated innate immunity in T2D patients has also been discovered to be due 
immune response caused by hyperglycaemia. However, it has not been discovered if immune 
activation occurs at the pre-diabetes stage. It has not been discovered if upregulation of 
inflammatory markers occurs at prediabetes stage. This study envisaged to characterise the 
changes that occur in immune cell concentration during the progression of pre-diabetic stage 
and if there is upregulation of inflammatory markers such as fibrinogen, CRP, CD40L, p-
selectin, IL-6 and TNF-α during pre-diabetic stage. To accomplish this, male Sprague Dawley 
rats were divided into two groups. The first group was fed a high-fat high-carbohydrate diet for 
20 weeks to induce pre-diabetes and the second group was fed a normal rat diet for 20 weeks.  
To confirm if the animals were pre-diabetic, criteria according to American Diabetes 
Association were used. The animals were then divided into 2 groups which is the pre-diabetic 
group with 6 animals and a non-diabetic control with another 6 animals. The animals were then 
further monitored for another 12 weeks (experimental period) while fed the same diet. Blood 
xxii 
 
was collected for haemocytometer analysis on week 0,4,8 and 12 of the experimental periods 
after which the animals were sacrificed. Plasma was collected from centrifuged blood for 
ELISA (TNF- α, CRP, P-selectin, CD40 L, fibrinogen & IL-6). Adipose tissue was collected 
for histology. The results showed a significant decrease in blood percentage count of   
neutrophils and eosinophils at week 12 experimental period and these immune cells were 
further observed embedded in-between the adipocytes of adipose tissue. This indicated that 
neutrophils and eosinophils are produced due to hyperglycaemia and then recruited to the 
inflamed area such as adipose tissue. The blood percentage count of lymphocytes, basophils 
and monocytes showed a significant increase at week 12, indicating their increase in production 
in the bone marrow during immune response. Additionally, the results showed a significant 
increase in inflammatory cytokines such as TNF-α, IL-6, CRP and P-selectin. The results also 
showed a slight increase in inflammatory markers such as CD40L and fibrinogen. These finding 
indicate that there is immune activation during pre-diabetes stage   due to changes in immune 
cells concentration and upregulation of inflammatory markers.
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CHAPTER 1: LITERATURE REVIEW 
1. Introduction 
Type 2 diabetes (T2D) is characterised by hyperglycaemia which contributes to metabolic and 
signalling abnormalities such as increased oxidative stress, activation of polyol pathway, 
activation of protein kinase C (PKC) pathway and formation of advanced glycation end 
products (1). However, the onset of T2D is often preceded by a long lasting condition called 
pre-diabetes (2). It still remains unclear if these metabolic and signalling abnormalities begin 
during the pre-diabetic stage. Kayal and Graves discovered that in T2D, hyperglycaemia causes 
increases in oxidative stress, shunting of polyol pathway ,activation of  PKC pathway and 
formation of advanced glycation end products (1). Furthermore, Kayal and Graves discovered 
these abnormalities lead to a dysregulated innate immunity system (1). According to literature, 
in T2D, during an immune response caused by hyperglycaemia there is increased production of 
immune cells such as neutrophils, basophils, lymphocytes, monocytes and eosinophils (3-10). 
It has also been discovered that tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) 
are elevated in T2D (11, 12). Furthermore, innate immunity dysregulation and chronic secretion 
of pro-inflammatory cytokines contribute to type 2 diabetes complications (1, 6, 13-15). The 
signalling and metabolic abnormalities caused by hyperglycaemia in T2D result in hyper-
reactive platelets (16). According to literature, T2D have elevated levels of P-selectin, soluble 
cluster of differentiation 40 ligand (CD40L) and C-reactive protein (CRP) which cause 
accumulation of platelets in vessel walls (17, 18). However, it also remains unclear if these 
changes occur during the pre-diabetes stage. One of the complications associated with T2D is 
atherosclerosis which leads to cardiovascular complications (19). Atherosclerosis is the 
hallmark of cardiovascular diseases characterised by hyperfibrinogenaemia due to clot 
formation, increased oxidised low-density lipoproteins (ox LDL) as well as decreased 
bioavailability of nitric oxide (NO) due to endothelial damage  (20-22). The endothelial damage 
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is caused by oxidative stress in T2D (23). However, it still remains unclear if pre-diabetics are 
at risk of developing atherosclerosis. Therefore, this study sought to evaluate the state of general 
immunity during the progression of pre-diabetes and accumulation of platelets in vessel wall at 
the pre-diabetes stage.  
1.2.  State of immunity in T2D 
T2D is associated with  insulin resistance results in hyperlipidaemia, hypertension which 
triggers the immune response (24, 25). According to Sindhu et al, in obese individuals and 
rodents, the chronic low grade systemic inflammation called metabolic inflammation has been 
to be a contributing factor associated with induction of insulin resistance and development of 
T2D (26). In obese subjects, metabolic inflammation with oxidative stress caused by the 
imbalance between free radicals and anti-oxidants has also been implicated to increase the 
progression of insulin resistance and development of T2D (27). However, due to chronic  
hyperglycaemia, the immune response is also said to be triggered by glucotoxicity (25). During 
the immune response there is increased production of immune cells such as neutrophils, 
monocytes, lymphocytes, eosinophils and basophils in the bone marrow (6, 8, 9, 28). These 
recruited immune cells play different roles in the immune system and contribute to 
inflammation and progression of type 2 diabetes (6, 8, 9). 
       1.2.1.  Neutrophils 
During hyperglycaemic conditions, the production of neutrophils is increased and according to 
literature they are the first immune cells to migrate from circulation to the inflamed area for 
immune response where they secrete cytokines such as TNF-α, interleukin-1 (IL-1) and IL-6 
(5). Furthermore, hyperglycaemia causes gradual formation and accumulation of neutrophil 
extracellular traps (5). This then results in neutrophils eliminating pathogens as an active 
constituent of innate immune system producing basal levels of IL-6 due to glucotoxicity  (5). 
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According to Papayannopoulos, due hyperglycaemia in T2D, ROS generated by nicotinamide 
adenine dinucleotide phosphate oxidase (NADPH oxidase) activates neutrophils resulting in 
activation of PKC (29). Additionally, Hatanaka et al discovered that the rise in intracellular Ca 
2+  of neutrophils in T2D which is triggered by hyperglycaemia and presence of AGEs stimulate 
cytokine release and accumulation, for inflammation in the inflamed areas (30). The 
accumulated and released cytokines activate phagocytes to release lytic proteins for 
phagocytosis (30, 31). The cytokines that are released by these chronically activated phagocytes 
then trigger apoptosis and cause more formation of ROS which further cause more 
inflammation contributing to progression of T2D (29). Cytokines secreted by neutrophils such 
as IL-6,IL-1β,TNF-α and IL-8 are responsible for inflammation, contributing to progression of 
T2D (5, 9). However, it remains unclear if these characteristics occur during the pre-diabetes 
stage. 
1.2.2. Lymphocytes 
Due to glucotoxicity caused by hyperglycaemia, there is increased production of lymphocytes 
in the bone marrow resulting in T-cells secreting the cytokines such as IL-6 for inflammation  
(8, 9). B-cells recruited mature into plasma cells and then secrete antibodies such as IgE, IgM. 
B-cells also secrete cytokines such as IL-6 during immune response for inflammation (4, 32). 
According to Libby, B and T lymphocytes has also been shown to be one of the immune cells 
that join the macrophages in the intima during the lesion evolution in the atherosclerosis, which 
is one of the T2D complications (33). This contributes to the progression of T2D. However, no 
studies have been done based on these characteristics during the pre-diabetes stage.  
1.2.3. Basophils 
The recruited basophils display the IgE antibody receptor on their surface (4, 34). Moreover, 
once they are recruited, they bind to IgE antibodies secreted by B-cells to activate them since 
high-carbohydrate diet is associated with increased IgE serum, causing release of cytokines 
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such as IL-6, VCAM-1 and IL-4 for inflammation (4, 32). Once the basophils are activated, 
they regulate eosinophil accumulation by activating a vascular cell adhesion molecule (VCAM-
1) which is required for the recruitment of eosinophils (8). According to Libby, VCAM-1 has 
also been observed to be able to bind precisely the types of leukocytes such as monocytes and  
T-lymphocytes in the early human and experimental atheroma during development of 
atherosclerosis (33). This contribute to the progression of T2D. However, it still a debatable 
issue if these characteristics occur at the pre-diabetes stage  
1.2.4. Eosinophils 
In T2D, the produced and circulating eosinophils has been shown to migrate to the inflamed 
area where they secrete cytokines such as IL-4 to sustain alternatively activated macrophages 
for inflammation which contribute to progression of T2D (35). According to Che et al, 
eosinophils are also required for the maintenance of plasma cells in the bone marrow (3). 
Secretion of cytokines by immune cells then result in the elevated levels of TNF-α and IL-6 for 
inflammation contributing to progression of T2D. However, the characteristics of eosinophils 
at pre-diabetes stage has never been discovered. 
1.2.5. Monocytes 
 Increased production of monocytes results in monocytes secreting cytokines upon activation 
during immune response (9). However, in the inflamed area the macrophages secrete cytokines 
such as monocyte chemoattractant protein-1 (MCP-1) due to inflammation (34). MCP-1 
expression then results in recruitment of monocytes to the inflamed area where they 
differentiate into macrophages secreting more cytokines for inflammation (10, 28, 36, 37). Due 
to hyperglycaemia, more monocytes are produced in the bone marrow resulting in monocytes 
taking up glucose to decrease their concentration to normal from circulation (38). Monocytes 
have been discovered to have glucose transporters allowing the uptake of glucose (38).  
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Furthermore, monocytes also respond to high carbohydrate diet by NADPH oxidase mediating 
high glucose induced nuclear factor kappa B (NF-kB) activation and releasing enhanced IL-6 
and IL-1β expression (10, 36, 39). NF-kB is also bought into play also by the macrophage 
contact with the medium from adipocytes resulting in release of cytokines for inflammation  
(40). Additionally, in T2D, monocytes have been shown to migrate to the intima where they 
differentiate to macrophages (41). Moreover these macrophages accumulate LDL and 
differentiate into foam cells in atherosclerosis (42, 43). These characteristics of monocytes 
contribute to the progression of T2D and progression of atherosclerosis in T2D. However, it 
remains unclear if these characteristics occur at pre-diabetic stage. Due to changes in immune 
cell concentration, formation of advanced glycation end product and increased oxidative stress, 
T2D patients are at high risk of atherosclerosis due to endothelial damage (19, 22, 44-46). 
1.3.  Increase in oxidative stress cause damage to endothelial cells  
According to Pitocco et al, the cardiovascular risk factors in diabetic conditions has been shown 
be induced by ROS production in the endothelial cells (22). Specifically, according to Kaneto 
et al, its hyperglycaemia that has been shown to induce ROS through activation of glycation 
reaction and electron transport chain in the mitochondria (47). Additionally, AGEs, insulin and 
angiotensin II  have also been shown to induce ROS through activation of the NADPH oxidase 
(47). According to Basta et al, AGEs in vasculature interact with the endothelial surface RAGE 
to induce intracellular ROS thereby activating the NADPH oxidase system (44). NADPH 
oxidase is the major source of ROS in vasculature (44). This production of ROS inactivates 
eNOS resulting in decreased NO levels in the endothelium which enable platelet adhesion and 
aggregation since NO inhibit platelet aggregation (44). Additionally, this production of ROS 
activates the NF-k B transcription factors which are highly relevant to inflammation, immunity 
and atherosclerosis (48).  
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Moreover, hyperglycaemia causes oxidative stress due to overproduction of reactive oxygen 
species (ROS), nitric oxide species (NS) and potent radicals such as hydrogen peroxide and 
superoxide anions (20, 22). This then causes damage to the endothelium and reduces the 
production of nitric oxide and prostacyclin which are potent vasodilators responsible for 
inhibiting platelet aggregation (49). Hypercholesterolemia is one of the characteristics of T2D  
(42).  
In our laboratory, we have shown that during the pre-diabetic stage the animals display 
increased LDL and decreased HDL levels (50). According to literature increased levels of LDL 
in T2D due to hypercholesterolemia result in LDL binding to the free radicals in the 
endothelium which then impair the endothelial nitric oxide synthase (eNOS) (42). Furthermore, 
nitric oxide can be oxidised by the superoxide ions due to oxidative stress leading to further 
reduction in its half-life and anti-platelet action (22). These circulating LDL bind to the free 
radicals in the endothelial cells to become oxidised LDL (oxLDL) (42). According to literature 
ox LDL impair endothelial nitric oxide synthase which then result in the decreased 
bioavailability of nitric oxide in the endothelial cells (42). Nitric oxide is a vasodilator for 
endothelial cells and also inhibit adhesion, aggregation and coagulation of platelets in the 
endothelial cells (22). Therefore, the absence of vasodilators causes vasoconstriction and 
promotes the accumulation of platelets in the damaged endothelium (22, 33, 51, 52). Increase 
in oxidative stress cause damage to the endothelial cells resulting in the denudation of the 
endothelium (53, 54).  
At the site of the vascular lesion, the extracellular matrix is exposed to blood stream thereby 
exposing the collagen and von Willebrand Factor (vWF) (54). Expression of vWF by damaged 
endothelium cause the recruitment of platelets to the endothelial wall (54). Collagen binds to 
glycoprotein Ia/IIa expressed by platelets and vWF bind to glycoprotein Ib/IX also expressed 
by platelets (54). According to literature, this then triggers the platelets to release the content 
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of their secretory vesicles, which contains variety of chemical agents such as adenosine 
diphosphate (ADP), thromboxane A2 and serotonin which act locally by inducing the change in 
metabolism, shape and surface proteins of platelets by process called activation of platelets (54, 
55). Binding of collagen and vWF to these proteins also results in activation of integrin α 11b β 
3 (GP11a/111b) which is a fibrinogen receptor for binding of fibrinogen (56). Furthermore, 
AGEs formed due to hyperglycaemia bind the advanced glycation end products receptor 
(RAGEs) to activate the circulating platelets (44).  
Upon activation, the platelet GP11a/111b is activated resulting in exposure to fibrinogen 
binding site (55, 57). This enables the recruitment of activated platelets to adhere to the adhered 
platelets that has already adhered to endothelial wall through binding to fibrinogen (57). This 
then forms the fibrinogen bridges linking platelets causing aggregation of platelets therefore 
accumulating in a vessel wall forming a platelet plug (57, 58). 
 Moreover, while a plug is built up and compacted, the vascular smooth muscle in the damaged 
vessel is then being stimulated to contract (58). This then decreases the blood flow in the area 
and change pressure in the vessel resulting in vasoconstriction (33). 
This vasoconstriction then results in a cascade of enzyme activations which requires platelets, 
plasma cofactors and calcium anions causing conversion of plasma protein prothrombin to 
enzyme thrombin (33, 59). Moreover, this thrombin then catalyses the reaction in which several 
polypeptides are split from molecules of large rod-shaped protein fibrinogen (59, 60). However, 
the fibrinogen remnants then bind to each other and then form fibrin which its chemical linking 
is enzymatically catalysed by factor XIIIa. Factor XIII is formed from plasma protein factor 
XIII catalysed by thrombin which stabilises the fibrin meshwork (59, 60). This result in a 
formation of a clot (59, 60).This formation of the clot is the foundation of development of 
cardiovascular complications in T2D due to atherosclerosis (19, 59). However, it remains 
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unclear if these characteristics occur at a pre-diabetes stage. Additionally, cytokines have been 
shown to be a link between the immune cells and inflammation (61). Cytokines such as IL-6 
and TNF-α influences immunity, inflammation and contribute to progression of T2D (11, 62, 
63). 
1.4.  Inflammatory Markers 
 1.4.1. TNF-α and IL-6 as markers of immunity in T2D 
It has been discovered that IL-6 and TNF-α are elevated in type 2 diabetes and they also 
contribute to progression of type 2 diabetes (12, 64-66). Interestingly, according to Pickup, 
these two cytokines have many pro-atherosclerotic actions including promotion of leukocyte 
recruitment to the endothelium by inducing the adhesion molecules and the synthesis of the 
chemoattractant and also raising the capillary permeability (61, 67, 68). These cytokines are 
also produced by the endothelium, smooth muscle cells and macrophages at the site of 
atherosclerosis (69). Furthermore, these two cytokines play a number of other roles contributing 
to changes in immune system, inflammation and progression of type 2 diabetes (61, 70, 71). 
Furthermore IL-6 has been discovered to be a pleiotropic cytokine (62, 65). According to 
literature this cytokine display pro and anti-inflammatory effects (65). It is secreted by a variety 
of tissues and cells which can be activated leukocytes, adipocytes, macrophages and endothelial 
cells (37, 72). Interestingly, IL-6 induces gluconeogenesis, hyperinsulinemia and 
hyperglycaemia which end up causing metabolic syndrome and then overt type 2 diabetes (72-
74). Monocytes play a central role in innate immunity by increasing secretion of IL-6 due to 
hyperglycaemia (39). However acute hyperglycaemia caused by insulin resistance due to high 
carbohydrate diet induces IL-6, TNF-α and IL-8 concentration (39, 75). Adiposity is also 
directly correlated with circulating levels of IL-6 and TNF-α (75). Exposure to chronic 
hyperglycaemic conditions also increase IL-6 secretion in 3T3-LI adipocytes(71, 76). 
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Moreover, in adipocytes, lipids induce endoplasmic reticulum stress by increasing JNK and 
extracellular receptor (77). 
Furthermore , high fat diets activate protein kinase C, NF-k B  and mitogen-activated protein 
kinase (MAPK) signalling which also contribute to cytokines production in 3T3-LI adipocytes 
(27). IL-6 inhibits lipoprotein lipase and stimulate lipolysis which then induce insulin resistance 
contributing to progression of type 2 diabetes (78). IL-6 secretion due to high fat diets also act 
upon insulin receptor substrate-1 when insulin is chronically elevated which then results in 
insulin availability phosphorylating IRS-1 on the serine residue to down regulate the 
phosphoinositide 3 kinase (PI3-K) (48, 79). This occurs via activation of mTor (rapamycin) 
which is activated by Akt (79). These 2 pathways activates protein kinase C signalling and 
nuclear factor kappa B pathway further cause chronic hyperglycaemia contributing to 
inflammation and progression of type 2 diabetes (79). However, the characteristic of IL-6 
remains unclear at pre-diabetes stage. 
Another cytokine elevated in type 2 diabetics is the monokine cytokine from the TNF family 
known as TNF-α (51). TNF-α is produced by macrophages and cells such as fibroblast, 
epithelial cells, adipocytes and myocytes (80). According to literature, this cytokine plays a role 
in the pathogenesis of insulin resistance since it is found elevated in adipocytes and plasma of 
insulin resistant subjects (66, 81). Furthermore, hyperglycaemia and hyperinsulinemia has been 
shown to increase the production of TNF-α from monocytes and macrophages in vitro (36, 74).  
Moreover, chronic hyperglycaemia activates macrophages and then stimulate TNF-α 
production (66). This increase the permeability of endothelium through release of nitric oxide 
by nitric oxide synthase which lead to depression of the myocardial myocytes (33, 51). This 
increase in TNF-α production also cause increase thrombogenesis through expression of 
plasminogen activator inhibitor -1 (PAI-1) and stimulate the expression of adhesion molecules 
on the endothelial cell (51, 55) 
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 Increase in TNF-α production also induces apoptosis in myocytes and endothelial cells which 
then contribute to heart failure through apoptosis (52, 82). This TNF-α production also activates 
the protein kinase C signalling and nuclear factor kappa B signalling (48, 79). Therefore, 
increased TNF-α production contribute to type 2 diabetics complications during progression of 
type 2 diabetes (48, 79). However, the state of TNF-α at pre-diabetes stage is still a debatable 
issue and has never been discovered. Furthermore, there are markers such as CRP and 
fibrinogen that have been shown to be elevated in T2D.  
1.4.2. C-reactive protein and fibrinogen as markers for events in atherosclerosis 
According to literature, CRP is from a pentraxin family of innate immune response proteins 
(18). According to Frostegard, the increased levels of c-reactive protein (CRP) have been 
implicated as a risk marker for atherosclerosis and the developed cardiovascular diseases in 
many studies (83-85). Furthermore, according to literature, CRP is an acute phase reactant of 
hepatic origin that is synthesized largely under the influence of IL-6(18, 86). CRP has also been 
discovered to be a mediator for atherogenesis by quenching nitric oxide (19). According to 
Badimon and Vilahur, CRP has been shown to exert a thrombotic activity (87). CRP monomeric 
form plays a role in platelet adhesion by initiating platelet deposition and also a thrombus 
growth (87). Moreover CRP dissociation from its pentameric form to monomeric form has been 
shown to occur in the surface of activated platelets (87). This dissociation process is supported 
by the activation of GPIIb/IIa (87). According to Bautista et al, CRP production by hepatocytes 
is also regulated by TNF-α causing atherosclerotic plaque and increased risk of high blood 
pressure resulting in hypertension (51). Moreover, CRP has been reported to display different 
immunoregulatory properties such as modulating platelets, opsonization, fixation of the 
complement system, enhancing leukocyte activity and mediation of LDL uptake by 
macrophages (19). CRP has also been discovered to be play active role in endothelial cells by 
inducing cellular adhesion molecule expression and inducing MCP-1 expression which induces 
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atherosclerosis (19). However, the characteristic of CRP is still yet to be discovered at pre-
diabetes stage. 
Additionally, fibrinogen is a complex plasma glycoprotein produced in the liver (88). This 
dimeric glycoprotein consists of three pairs of di-sulphide bonded polypeptide chains which are 
Aα, Bβ and the ɣ-chains (89). Fibrinogen plays a role in influencing plasma viscosity, 
deposition of fibrin, aggregation of platelets and has been recognised as a role player in 
atherosclerosis (88, 89).  According to Dunn et al, thrombin activates fibrinogen during clot 
formation in atherosclerosis by cleaving two small peptides designated fibrinopeptide A (FPA) 
and fibrinopeptide B (FPB) from the N-terminal parts of Aα-chains and Bβ-chains respectively 
(89). These activated fibrinogen molecules can then form a complex of fibrin and fibrinogen 
molecules (89).  
Additionally, thrombin induces the formation of fibrin from fibrinogen (59). This step is then 
followed by cascade of events that contribute to clot formation (59). According to literature, 
the T2D display elevated levels of plasma fibrinogen have been linked to development of 
cardiovascular disease (21).This progression then cause more diabetics complications leading 
to cardiovascular diseases such as heart failure, stroke, angina. myocardial infarction 
(18).However the characteristic of  fibrinogen remains unclear at pre-diabetes stage. P-selectin 
(s) and CD40L (s) has been shown to be the markers for platelet activation and aggregation in 
T2D (17, 56, 90, 91). 
1.4.3. Soluble P-selectin and soluble CD40L as inflammatory markers 
According to Carter et al, soluble P-selectin is the cell adhesion molecule responsible for 
attachment of leukocytes to the damaged endothelium and platelets (92). Soluble P-selectin is 
the marker for platelet activation (54). It is stored in the α granules of platelets and in endothelial 
cell Wiebel Palade bodies (92). Moreover, upon activation of platelets and endothelial cells 
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soluble P-selectin secreted (92). P-selectin plays different roles in the such as platelet rolling to 
the dysfunctional/damaged endothelium, supporting leukocyte rolling to the damaged 
endothelium and also platelet-leukocyte adhesion (92). Soluble P-selectin prevent adhesion to 
the vessel wall by binding to P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes. T2D 
and ischemic heart diseases has been shown to have elevated levels of P-selectin (s) (92). 
However, it remains unclear if pre-diabetics display the same characteristic of soluble P-
selectin. 
Soluble CD40L is the 35kDa glycoprotein from the TNF-α  family (93, 94). According to 
Vaidyula et al, his pro-inflammatory member has been shown to be elevated in T2D (94). In 
circulation, it is stored and expressed in platelet surfaces (94). It confirms the firm binding of 
platelets to the damaged endothelial wall (54). Upon expression soluble CD40L interacts with 
cells that display its receptor CD40 for binding resulting in expression of adhesion molecules 
(94). It has been shown to interact with cells such as endothelial cells, monocytes and 
macrophages (94). However, it remains unclear if soluble CD40L is secreted by cells at pre-
diabetic stage. In T2D activation of inflammatory signalling mechanisms contribute to the 
increase in inflammation and progression of T2D (48, 79) 
1.5. Activation of c-Jun-N-terminal kinase (JNK) and inhibitor kappa B kinase (IKKβ) 
 Oxidative stress, hyperglycaemia, hyperlipidaemia and cytokines such as TNF-α and IL-6 
cause activation of c-Jun-N-terminal kinase (JNK) and inhibitor kappa B kinase (IKKβ) (80, 
95). This activation causes a serine phosphorylation of insulin receptor-1 (IRS-1) and insulin 
receptor-2 (IRS-2) which then impair the insulin signalling pathway (79, 80, 95). This result in 
insulin resistance (80). Interestingly this phosphorylation also causes translocation of NF-k B 
and activator protein-1 (AP-1) from the cytoplasm to the nucleus inducing more inflammation 
which then contribute to progression of type 2 diabetes (48, 80). According to Zanergar et al, 
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CD40L ligation has also been shown to activate NF-K B transcription factors which are known 
to be the major regulators of the immune and inflammatory response (93). However, it is still a 
debatable issue if this occur at a pre-diabetic stage. Henceforth, all these abnormalities have 
been discovered to be linked to consumption of an unhealthy diet as the primary source (96-
98). High fat diets have been shown to have an effect on immunity due to insulin resistance 
(98).  
1.6. High-fat diet and immunity 
According to Sindhu et al, obese individuals and T2D have elevated levels of free fatty acids 
(FFAs) which has been shown to be  related to immune function (99). Saturated fatty acids 
(SFAs) such as palmitate has been shown to show inflammatory effect on 
monocytes/macrophages and TLR signalling system (95, 99). FFAs has also been shown to 
activate the innate immune system via the TLR4 which is important in  high-fat induced insulin 
resistance (99). Additionally, palmitate has been reported to induce pro-inflammatory cytokines 
such as TNF-α,IL-1β, IL-8 and IL-6 (99). 
Kim et al, investigated the effect HFD using 2 experimental groups for a period of 8 weeks 
(98). The C57BL/6j mice were fed low fat diet (LFD) consisting of 10 kcal % fat and the second 
group fed  HFD consisting of 60 kcal % fat (98). ELISA was used to test for the levels of TNF-
α,IL-1β and IL-6 which was discovered to be elevated in HFD mice in comparison with LFD 
fed mice (98). Using immunoblotting ,they also discovered that there was an increase in 
TLR4,inducible NOS and activation of NF-KB in the intestines of the HFD fed mice in 
comparison with the LFD fed mice (98). In conclusion to their research HFD was found to 
induce inflammation through TLR4 induction and NF-KB activation resulting in increase in 
cytokines contributing to inflammation (95, 98). However, the effect of HFD is still a debatable 
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issue at the pre-diabetes stage. High-carbohydrate diet has also been shown to have effect on 
immunity due to insulin resistance.     
1.7. High carbohydrate diet and immunity 
High-carbohydrate diets induce elevated levels of glucose also known as hyperglycaemia (100). 
The consequences of hyperglycaemia has been shown to cause different mechanisms such 
increased flux through polyol pathway which contribute to oxidative stress (1). Activation of 
PKC due to hyperglycaemia can lead to increased diacylglycerol (DAG) since in a 
hyperglycaemic condition dihydroxy acetone phosphate become elevated and in some tissues, 
it is reduced to glycerol phosphate and converted to diacylglycerol (1). Activation of PKC-θ by 
DAG may cause insulin resistance in muscle through IRS-1 associated PI3K activity (1). 
Similarly, the activation of PKC-ε by DAG may cause insulin resistance to liver (100). However 
the high-fat high-carbohydrate diet has been discovered to be a factor contributing to pre-
diabetes (101). 
1.8. Justification of the study 
The pre-diabetic model has been discovered using high-fat high-carbohydrate diet (50). This 
pre-diabetic model was discovered using values 6.1 to 6.9 mmol/L for impaired fasting glucose 
(IFG), 7,8 to 11.0 mmol/L impaired glucose tolerance (IGT) at two hour plasma glucose 
administration and glycated hemoglobin (HbA1c) of  5.7 % to 6.4 % considered pre-
diabetic(50, 101). This glycated haemoglobin range is in line with the National Health and 
Nutrition Examination Survey (NHANES) data (50, 101). 
Literature has shown that HFD cause insulin resistance in different mechanisms (25, 102-105). 
It has also been discovered that high-carbohydrate diet also causes insulin resistance in different 
mechanisms (1, 74). Both dietary groups (HFD and HCD) has been shown to also induce 
inflammation through activation of inflammatory signaling pathways such as NF-K B and 
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MAPKs (27, 79). Therefore, a combination of these two diets is hypothesised to induce more 
insulin resistance and result in more inflammation.   
Literature has shown the effect of continuous consumption of unhealthy diet such as high-fat 
high-carbohydrate diet and living a sedentary lifestyle lead to T2D (96, 106, 107). Furthermore, 
according to literature it has also been shown that a long-lasting condition called pre-diabetes 
leads to T2D (50). The pre-diabetic model discovered in our laboratory mimicked the western 
diet consumed by human beings with sedentary lifestyle as these male pre-diabetic Sprague 
dawley rats were not exercising.  
Additionally, literature has also shown that T2D have compromised immunity (1, 28). 
However, it remains unclear if a high-fat high-carbohydrate diet is the primary cause of the 
changes in quantity and functioning of immune cells. It also remains unclear if the immune 
activation occurs during progression of pre-diabetic stage to T2D. According to literature, it 
has been discovered that high-fat diet and high-carbohydrates diet cause secretion of 
inflammatory markers such IL-6 and TNFα (98, 108). Literature has also shown that 
inflammatory markers such as fibrinogen, CRP, CD40L, p-selectin, IL-6 and TNF-α are 
elevated in type 2 diabetic patients, but it still remains unclear if these inflammatory markers 
are secreted during progression of pre-diabetic stage. This study will characterise the clear 
understanding of the effect of this diet on neutrophils, monocytes, lymphocytes, eosinophils 
and basophils at pre-diabetic state in relation to changes that occur in T2D. Furthermore, there 
will be more clarity if there is secretion of the inflammatory markers (fibrinogen, CRP, CD40L, 





1.9. Aim  
The aim of this study is to characterise the changes in immune cell concentration during the 
progression of pre-diabetes to type 2 diabetes and accumulation of platelets in vessel wall at 
pre-diabetic stage in a diet-induced pre-diabetic rat model. 
1.10. Objectives 
To determine the response of immune cells after consumption of high-fat high-carbohydrate 
diet during progression of pre-diabetes to type 2 diabetes. 
Evaluate the level of secretion of inflammatory markers at pre-diabetic stage.   
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Pre-diabetes has been shown to be caused by consumption of an unhealthy diet and living a 
sedentary lifestyle. Pre-diabetics have also been shown to be on a pre-diabetic stage for about 
20 years before they become type 2 diabetic. However, combination of high-fat diet and high-
carbohydrate diet has been shown to be the source of diet contributing to insulin resistance in 
pre-diabetics. Once they are type 2 diabetic, their immune system become compromised with 
elevated levels of IL-6, TNF-α, fibrinogen, C-reactive protein, P-selectin and CD40L which 
contributes to the progression of type 2 diabetes. Furthermore, type 2 diabetics develop 
complications due to dysregulated innate immunity such as atherosclerosis which then lead to 
cardiovascular diseases. However, it’s a debatable issue if the immune activation and 
inflammation occur at the pre-diabetic stage. It’s still a debatable issue if changes in immune 
cell concentrations and upregulation of inflammatory markers is a contributing factor of the 
progression of pre -diabetes stage to type 2 diabetes. Therefore, the present study evaluated if 
there are any changes in immune cell concentration in circulation during progression of pre-
diabetes to type 2 diabetes in a diet-induced pre-diabetic rat model. It also evaluates if they are 
any immune cells in inflamed area and if there is any upregulation of the inflammatory markers 
such as IL-6, TNF-α, fibrinogen, C-reactive protein, P-selectin and CD40L at pre-diabetes stage 
in a diet-induced pre-diabetes rat model. 
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Pre-diabetes is a long-lasting condition that precedes type 2 diabetes (T2D). T2D has been 
shown to suppress the immune response. However, it remains unclear if immune activation 
occurs before the onset of T2D during the progression of the pre-diabetic state. This study 
sought to characterise the changes in general immunity occurring during the progression from 
pre-diabetes to T2D. Male rats were fed a high-fat high-carbohydrate diet for 20 weeks (pre-
diabetes induction period) and kept on the same diet being monitored for a further 12 weeks 
(experimental period). Blood was collected for haemocytometer analysis on week 0,4,8 and 12 
of the experimental periods after which the animals were sacrificed. Plasma was collected from 
centrifuged blood for ELISA (TNF- α, CRP, P-selectin, CD40 L, fibrinogen & IL-6). Blood 
neutrophils percentage significantly decreased at week 12 possibly due to recruited neutrophils 
migrating to an inflamed area such as visceral adipose tissue as further observed. Due to 
hyperglycaemia there was significant increase in blood lymphocytes percentage at week 12. 
Blood monocytes percentage significantly increased at week 12. Monocytes recruited and 
circulated in blood due to hyperglycaemia for glucose uptake to decrease it from circulation. 
Blood eosinophils percentage significantly decreased at week 12. Eosinophils migrated to 
inflamed areas such as visceral adipose tissue as further observed. Blood basophils percentage 
significantly increased due to their recruitment and activation. TNF- α, CRP and IL-6 increased 
significantly after 12 weeks. There was also upregulation of fibrinogen, P-selectin and CD40L. 
The results of this study show that there are changes in immune cells concentration and that 
immune cells such as neutrophils and eosinophils migrate to inflamed areas such as adipose 
tissue. There is also upregulation of various inflammatory cytokines. Based on these findings, 


























According to the World Health Organisation, the global prevalence of type 2 diabetes (T2D) 
has risen from 4.7 % to 8.5 % among adults in the last 34 years (1, 2). In  2014 ,422 million 
adults were living with diabetes in comparison with the 108 million adults shown in 1980 (2).  
The pre-disposing factors are the continuous consumption of an unhealthy diet and living a 
sedentary lifestyle (1). Type 2 diabetic  patients have been shown to have compromised 
immunity (3). Studies show that in type 2 diabetes there is an increase in the production of 
adipocytes and chemokines in the immune system due to cell dysfunction and insulin resistance 
(4). Obese individuals and rodents have been shown to be associated with chronic low-grade 
systemic inflammation called metabolic inflammation, which is another contributing factor that 
induces insulin resistance and T2D (2, 5-7). The chemokines and cytokines produced by 
adipose tissue have been shown to contribute to metabolic inflammation  in  obese individuals 
and rodents (6). However, according to Ahmad et al, free fatty acids that are circulating in blood 
of obese and T2D individuals have been shown to act on toll like receptors (TLR2 and TLR 4) 
to promote inflammatory signalling (7, 8). Additionally, in obese individuals, the imbalance 
between the free radicals and anti-oxidants caused by oxidative stress with the metabolic 
inflammation has been shown to also lead to risk of development of T2D (8). According to 
Graves and Kayal, hyperglycaemia causes disturbances of signalling factors (9). These include 
increased oxidative stress, elevated protein kinase C activation, shunting of the polyol pathway 
and increased formation of advanced glycation end products (9). Studies have shown that there 
is increased migration of neutrophils and simultaneous increases in lymphocyte activation (10, 
11). Furthermore, monocytes are recruited and differentiate into macrophages which cause 
more secretion of cytokines for inflammation (12, 13). Additionally, eosinophils secrete 
cytokines that sustain macrophage activation causing additional secretion of cytokines for 
inflammation (14). This results in type 2 diabetic patients having increased levels of cytokines 
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like TNF-α and IL-6 (15, 16). Type 2 diabetic patients have also been shown to have elevated 
levels of C-reactive protein, fibrinogen, P-selectin and CD40 ligand (17-20). However, the 
profile of these markers is still remaining unclear at the pre-diabetic stage. The onset of T2D is 
usually preceded by a long lasting condition known as pre-diabetes which is characterized by 
glycated haemoglobin levels ranging from 5.7 % to 6.4 % (21). The effect of this condition on 
immune cells and various changes that occur during the progression to T2D are yet to be fully 
characterised. Recently, we have reported on a diet-induced pre-diabetic animal model that 
satisfies diagnosis as set out by the American Diabetes Association (21, 22). We have further 
shown that the continued exposure of the pre-diabetic animals to a high-fat high-carbohydrate 
diet for another 12 weeks result in the development of T2D (23). Based on this knowledge, this 
study sought to characterise the changes in the concentration of immune cells that occur during 
the progression from pre-diabetes to T2D.  
2.2. Materials and methods 
2.2.1. Drugs and Chemicals 
All chemicals and reagents were sourced from the standard pharmaceutical suppliers and were 
of analytical grade. The materials and kits were sourced as follows: EDTA tubes (Greiner bio-
one, Monroe, USA); Heparinized containers (Greiner bio-one, Monroe, USA); Glucose sticks 
(Mzansi Medical Supplies, Durban, South Africa); Rat TNF-α, CRP, P-selectin, CD40L, 
fibrinogen, glycated hemoglobin, IL-6 ELISA kits (Elabscience, Texas, USA). 
2.2.2. Animal Studies  
A group of male Sprague Dawley rats (150-180g) bred and kept at the Biomedical Research 
Unit (BRU) from the University of Kwa Zulu-Natal were used in the study. They were 
maintained under standard laboratory condition at temperature 22±2 °C and relative humidity 
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of (55±5%) and illumination (12h light/dark circle). The level of noise was maintained at less 
than 65 decibels and animals allowed access to food and fluids ad libitum. All animal 
procedures and housing conditions were approved by Animal Research Ethics committee of the 
University of Kwa Zulu-Natal (ethics no.: AREC/035/016M).  
2.2.3. Induction of Pre-diabetes  
Pre-diabetes was induced using a well-established laboratory protocol (21). Briefly, animals 
were divided into 2 groups at the beginning of an experiment. The first group animals were 
exposed to a high-fat high-carbohydrate diet supplemented with 15% fructose for 20 weeks 
(induction period). The second group of animals which was a control group  was then fed 
standard rat diet for 20 weeks (21, 24). After 20 weeks, animals that exhibited the criteria 
according to American Diabetes Association with impaired fasting blood glucose concentration 
of 6,1 to 6.9 mmol/L, impaired glucose tolerance of 7.8-11.0mmol/L, and glycated 
haemoglobin of 5.7-6.4% were then considered to be pre-diabetic (21, 25). 
 2.2.4. Experimental design 
At the end of 20-week induction period, the animals were then divided into the non-diabetic 
control (NC) and the high-fat high-carbohydrate diet induced pre-diabetic group (PD) according 
to the results obtained from their health condition. Six rats (n=6) from the control group were 
used and another six rats were used from the pre-diabetic induced group (n=6). Both groups of 
rats were monitored for a further 12-week experimental period while carrying on with their diet. 
Parameters including neutrophils, lymphocytes, monocytes, eosinophils and basophils were 
measured every 4th week of the experimental period using a haemocytometer (Beckman 
Coulter, Indianapolis, United States). At the end of the experimental period the animals were 
sacrificed by being anaesthetised with Isofor (100mg/kg) (Safeline Pharmaceuticals (Pty) Ltd, 
40 
 
Roodeport, South Africa) via gas anaesthetic chamber (Biomedical Resource Unit, UKZN, 
Durban, South Africa) for 3 minutes.  
2.2.5. Blood and tissue collection 
Blood was collected by cardiac puncture and then injected into individual pre-cooled 
heparinized containers while the rats were unconscious. EDTA tubes were used to collect 
plasma for (TNF- α, CRP, P-selectin, CD40L, fibrinogen, glycated hemoglobin and IL-6) 
ELISA and lipid profile. The blood was centrifuged for 15 minutes at 1000 × g (2-8°C).  
Adipose tissue was collected for histology. 
2.2.6. Oral glucose tolerance (OGTT) response  
Both groups of animals were exposed to a 18-hour fasting period before OGT response and 
monitored during OGT test according to our established laboratory protocol (26). Briefly, after 
an 18-hour fasting period, glucose was measured (time 0) followed by loading of a 
monosaccharide syrup (glucose;0.86 g/kg. p. o) by oral gavage using an 18-gauge gavage 
needle that is 38mm long curved, with a 21/4 mm ball end (Able Scientific, Canning Vale, 
Australia). For glucose concentration measurement, blood was collected using a tail-prick 
method and glucose concentrations were measured using a OneTouch select glucometer 
(Lifescan, Mosta, Malta, United Kingdom). Glucose concentrations were measured in different 
time intervals which are 15, 30, 60 and 120 minutes after carbohydrate loading orally. 
2.2.7. Plasma glucose and triglyceride measurements  
Plasma glucose and triglycerides concentration was measured using a tail prick method to 
collect blood. For blood glucose measurement, a OneTouch select glucometer (Lifescan, Mosta, 
Malta, United Kingdom) was used, at the end of experimental period in both groups i.e. non-
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diabetic (NC) and pre-diabetic group (PD). For triglycerides measurement, Accutrend Plus 
multi test kit (Roche diagnostics, Reinach, Switzerland) was used in every fourth week of 
experimental period.  
2.2.8. Blood pressure measurements 
Non-invasive tail cuff method with photoelectric sensors (IITC Model 31 Computerised Blood 
Pressure Monitor, Life Sciences, Woodland Hills, California, USA) was used to measure 
systolic, diastolic and mean arterial pressure (MAP). Both animal groups were monitored at 
week 0 of experimental period and week 12 which is the end of experimental period (21). The 
equipment was calibrated each day prior to measurements. The animals were kept warm at ± 
30°C   in an enclosed chamber (IITC Model 303sc Animal Test Chamber, IITC Life Sciences, 
Woodlands Hills, California, USA) for 30 minutes before blood pressure recording. All 
measurements were conducted at 09h00. 
2.2.9. Inflammatory marker measurements 
TNF- α, CRP, fibrinogen, P-selectin, CD40L and IL-6 were measured using their respective 
ELISA kits from Elabscience as per manufacturer instructions. The optical density was 
determined of each well using a Spectrostar nanoplate spectrophotometer (BMG Labtech, 
Ortenburg, Baden-Württernberg, Germany) at 450 nm.   
2.2.10. Plasma lipid profile concentration measurements 
At the end of experimental period, plasma total cholesterol (TC), triglycerides (TG), low-
density lipoprotein (LDL) and high-density lipoprotein (HDL) concentrations were measured 
by the Global Clinical and Viral Laboratory (Amanzimtoti, South Africa). Friedewald’s 
equation was used to calculate the LDL concentrations. 
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2.2.11. Histology of adipose tissue   
Histological technique was performed according to the protocol which was modified based on 
the technique by Jali et al. Briefly, harvested tissue was fixed in formalin (fixative) and then 
dehydrated in alcohol (27). It was then cleared using xylene followed by embedding with 
molten wax to replace water and forming moulds with labelled cassettes for sectioning. 
Microtomy was used for sectioning  followed by mounting of sections into slides that were kept 
overnight to dry (27). The slides were then cleared in xylene and then dehydrated in alcohol 
followed by haematoxylin and eosin (H&E) staining. Using an applicator, distyrene plasticizer 
xylene (DPX) mounting glue was dropped directly over the tissue section. An appropriate sized 
coverslip was then gentle lowered over the DPX ensuring no air bubbles are trapped. The slides 
were then left to dry overnight and then the photomicrographs were viewed on the digital light 
microscope using Leica application suit (version 3.4.0). 
 
2.3. Statistics 
Data is expressed as means ± standard error of means (SEM). Statistical analysis was conducted 
using Graph Pad Prism Instant Software (version 5.00, graph Pad Software, San Diego, 
California, USA).  Two-way analysis of variance (ANOVA) was used to analyse differences 
between the controls and the experimental groups of immune cells at different time intervals 
while the unpaired t-test was used to analyse the results of inflammatory markers at the end of 
experimental period. Two-way ANOVA was followed by Bonferroni post hoc comparison test.  






2.4.1. Glycated haemoglobin (HbA1c) and mean arterial pressure  
At the end of the induction and experimental periods, animals were sacrificed, and glycated 
haemoglobin was measured in both the non-diabetic control (NC) and pre-diabetic group (PD).  
The results showed that the HbA1c of PD was in the pre-diabetic range at week 20 and had 
increased to within the range of type 2 diabetes by week 32 (see Table 1). Table 1 also shows 
the mean arterial pressure at measured at week 20 and week 32 in both the non-diabetic control 
(NC) and pre-diabetic group (PD) to determine if there is any change in blood pressure during 
the pre-diabetic stage. The results show that the MAP significantly (p<0.05) increased at the 
end of induction period (week 20) as well as at week 32, which is the end of experimental 
period. [Insert table 1 here]. 
2.4.2. Plasma lipid profile 
Table 2 shows the plasma lipid profile at the end of the experimental period (week 32) of both 
non-diabetic control (NC) and pre-diabetic group (PD) to determine the concentration of 
various types of plasma lipids in pre-diabetes. The results show that there was a significant 
(p<0.05) increase LDL with a concomitant significant (p<0.05) decrease in plasma HDL of the 
pre-diabetic group (PD) in comparison with a non-diabetic control (NC). [Insert table 2 here] 
2.4.3. Plasma glucose and triglyceride levels  
At the end of experimental period, plasma glucose and triglyceride levels were measured in 
both non-diabetic control (NC) and pre-diabetic group (PD). The results showed a significant 
(p<0.05) increase in plasma glucose levels of pre-diabetic group (PD) in comparison with a 
non-diabetic control (NC) as shown in figure 1a. Figure 1b shows a significant (p<0.001) 
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increase in triglycerides from week 4 to week 12 in the pre-diabetic group (PD) by comparison 
with the non-diabetic group (NC). (see figure 1b) 
2.4.4. OGTT response 
 At the end of experimental period, both the groups NC and PD were exposed to 12 hours fasting 
and glucose was measured followed by the oral administration of monosaccharide syrup 
(glucose ;0,86 g/kg, p. o) at different time intervals (15, 30, 60 and 120 minutes) to assess 
glucose tolerance. The results showed a significant (p<0.05) increase in glucose concentration 
at 15, 30, 60 and 120 minutes in the pre-diabetic group (PD) by comparison with the non-
diabetic control (NC) as shown in figure 2.   
2.4.5. Neutrophil count 
The experimental groups, NC and PD percentage count of blood neutrophils were monitored 
every fourth week of the experimental period (week 0, 4, 8, 12) to determine if there was any 
change in neutrophil concentration at the pre-diabetic stage. The results showed that the pre-
diabetic group (PD) had a significantly (p<0.05) decreased blood neutrophil count at week 8 
and showed more significant (p<0.05) decrease at week 12 of the experimental period by 
comparison with the non-diabetic control (NC) at the corresponding time intervals as shown in 
figure 3.  
2.4.6. Histology of visceral adipose tissue  
The visceral adipose tissue histology from the abdominal area of rats were performed for both 
non-diabetic control and pre-diabetic group at the end of the experimental period to observe for 
the presence of immune cells. The illustration from the photomicrographs obtained displayed 
that there were no immune cells found in non-diabetic control adipose tissue. However, the 
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photomicrographs of the pre-diabetic group showed neutrophil (image B) and eosinophil 
(image D) located in-between the adipocytes and infiltration sites spotted by pinkish stained 
cytoplasm (shown in image D) as shown in figure 4. 
2.4.7. Lymphocyte count 
The percentage count of blood lymphocytes was monitored in both the NC and PD experimental 
groups every fourth week of the experimental period (week 0, 4 ,8, 12) to determine if they are 
produced at pre-diabetic stage during immune response. The results showed that pre-diabetic 
group (PD) had a significantly (p< 0.05) increased blood lymphocytes count at week 12 of the 
experimental period by comparison with non-diabetic control (NC) at corresponding time 
intervals as shown in figure5. 
2.4.8. Monocyte count 
The monitored percentage count of blood monocytes in both the NC and PD experimental 
groups every fourth week of the experimental period (week 0,4,8,12) was measured to monitor 
if they are any produced monocytes produced and circulating in blood during immune response 
at pre-diabetes stage.  Results showed that pre-diabetic group (PD) had a significantly (p<0.05) 
increased percentage count of blood monocytes at week 8 and 12 of the experimental period by 
comparison with the non-diabetic control. See figure 6. 
2.4.9. Eosinophil count 
The percentage count of blood eosinophils was monitored in both the NC and PD experimental 
groups every fourth week of the experimental period (week 0, 4, 8, 12). The results showed that 
pre-diabetic group (PD) had a significantly (p<0.05) decreased blood lymphocytes count at 
46 
 
week 12 of the experimental period by comparison with the non-diabetic control (NC) at the 
corresponding time intervals as shown in figure 7.  
2.4.10. Basophil count 
The percentage count of blood basophils was monitored in both the NC and PD experimental 
groups every fourth week of the experimental period (week 0, 4, 8, 12). The results showed that 
the pre-diabetic group (PD) had a significantly (p<0.05) increased blood lymphocyte count at 
week 12 of the experimental period by comparison with non-diabetic control (NC) at the 
corresponding time interval as shown in figure 8.  
2.4.11. Inflammatory markers concentration  
Plasma inflammatory marker concentration was measured in both experimental groups at the 
end of the experimental period. The results showed that PD had significantly (p<0.05) increased 
plasma levels of TNF-α, IL-6, CRP and P-selectin in comparison to NC. (see fig 9a, 9b, 9c, 9f). 
Figure 9d and 9e show an increase in fibrinogen and CD40L levels of PD by comparison with 
ND. 
2.5. Discussion 
Pre-diabetes is a long-lasting condition that precedes T2D (25). According to literature, type 2 
diabetes compromises the immune system which is associated with the recruitment of immune 
cells and release of pro- inflammatory cytokines (28). This results in the recruitment of immune 
cells and release of pro-inflammatory cytokines (3, 29, 30). However, no studies have been 
done to characterise the changes in immune cell concentration during the progression of pre-
diabetes to overt T2D. This study, therefore, was designed to focus on the changes that occur 
on immune cell concentration during pre-diabetes leading to the development of T2D. 
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In our laboratory, we have established a pre-diabetic rat model based on the American Diabetic 
Association criteria (21, 24, 25). After 20 weeks of pre-diabetes induction, the animals were 
observed for an additional 12 weeks to investigate the immunological changes that occur during 
the progression to T2D. Interestingly, after 12 weeks the haematological measure of glycated 
haemoglobin (HbA1c) increased to 6.6 % which indicated the progression to type 2 diabetes 
(25). Literature evidence suggests that hyperglycaemia leads to hypertension, hyperlipidaemia 
and inflammation contributing to type 2 diabetes (31). Furthermore, according to literature, it 
is hyperglycaemia that triggers the immune response even though it may not result in elevated 
levels of pro-inflammatory cytokines as compared to conditions in T2D (9).  
However, according to the results of this study, there was an evident immune response and 
release of cytokines during the pre-diabetic state which is not characterized by hyperglycaemia 
but raised HbA1c. During this state, the cells have not completely lost their sensitivity to insulin, 
however, it is a slow progression that occurs due to the impairment of insulin signalling pathway 
(32, 33). Therefore, during pre-diabetes there is fluctuation of glucose levels as it progresses to 
fully impaired insulin signalling pathway resulting in insulin resistance (32, 34). According to 
Graves and Kayal, in diabetes, hyperglycaemia also contributes to metabolic and signalling 
abnormalities, however it has never been discovered if these abnormalities contribute to 
immunological changes during the pre-diabetes stage. Hyperglycaemia has been found to 
influence fluctuating concentrations of immune cells (35). In this study, we measured their 
concentrations at different time intervals through the progression of pre-diabetes to T2D. It has 
been discovered that neutrophils are the first line of defence and they migrate to an inflamed 
area in response to insulin resistance, lipotoxicity and glucotoxicity in T2D (10). Neutrophils 
then secrete pro-inflammatory cytokines such as TNF-α & IL-6 resulting in more inflammation 
and activation of NF-k B (10, 36). This then causes more insulin resistance through activation 
of serine residue of insulin receptor substrate thereby impairing the insulin signalling pathway 
48 
 
and causing more inflammation (37). Theoretically, expanding adipose tissue due to fat 
accumulation causes insulin resistance which attract neutrophils for inflammation (38). This 
correlates with the observed histology of adipose tissue of pre-diabetic group displaying 
neutrophil embedded in-between the adipocytes. During a hyperglycaemic state, the neutrophils 
form extracellular traps (36). After a high-fat meal, the neutrophils are recruited thus increasing 
their concentration in blood causing migration to adipose tissue (10). This correlates with the 
observed increase at week 4 showing that the neutrophils were recruited in bone marrow and 
circulating in blood and the subsequent decrease observed in blood from week 8 and week 12 
showing that they were migrating to the inflamed areas such as adipose tissue as observed in 
histology obtained.  
Lymphocytes such as B-cell mature to plasma cells and release more antibodies such as IgE 
antibodies in T2D patients which then bind to recruited basophils to activate them and secrete 
pro inflammatory cytokines (37, 39). This results in elevated levels of basophils and over-
activated basophils in T2D. Denzel et al also mentioned that basophils are the main source of 
IL-4 and IL-6 in spleen and bone marrow after being stimulated by IL-3 and crosslinking with 
IgE receptors (39). The memory B-cell express IgG and IgE which allows them to recognise 
and react to free antigen (39, 40). The basophils then bind to IgE antibodies released and then 
over activated which correlates with the increase in concentration of basophils in pre-diabetic 
group at week 12 during progression of pre-diabetes. However, as the immune system becomes 
more compromised, more basophils will be recruited contributing to onset of T2D. 
In this study, we observed that the concentration of lymphocytes increased in the pre-diabetic 
group at week 12 of the experimental period. We can speculate that the progression of insulin 
resistance triggers the immune system and recruitment of lymphocytes from the bone marrow. 
According to Patel et al, differentiation of B-cells into plasma cells require activity from antigen 
specific CD4+ T cells. Additionally CD8+ T cells promote adipose tissue macrophages 
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accumulation and pro-inflammatory cytokines gene expression (41). Due to high-fat high-
carbohydrate diet, IL-6 is secreted which then stimulates differentiation of T and B cells, 
secretion of immunoglobulins, proliferation of thymocytes, and expression of acute-phase 
proteins in the liver (37). Furthermore, macrophages are classically activated and then secrete 
large amounts of pro-inflammatory cytokines and express high levels of costimulatory 
molecules which are required for T-cell activation (37, 42). Moreover these macrophages are 
potentially capable of presenting necrotic cell-derived antigens to T-cells and B-cells (42). This 
then activates adaptive immunity, resulting in clonal expansion of CD4+Th1 cells and 
recruitment of CD8+T-cells (37). This correlates with the increase in percentage count of blood 
lymphocytes of pre-diabetic group at week 12.   
Theoretically monocytes secrete cytokines such as TNF-α and IL-6 which also activate the NF-
kB pathway causing chronic inflammation in T2D (37, 43). Moreover monocytes also 
differentiate into macrophages and then secrete more pro-inflammatory cytokines such as 
monocyte chemo attractant, TNF-α and IL-6 which cause chronic inflammation and progression 
of T2D (43). The results of this study showed that there was an increase in percentage cell count 
of blood monocytes in circulation during the pre-diabetic state. Insulin resistance in the adipose 
tissue result in secretion of cytokines such as IL-6, TNF- α and MCP-1 (12). During an immune 
response, IL-6 causes increase in the concentration of monocytes in blood (44). The changes in 
the immune system functioning that occur in in obesity and T2D has been shown to contribute 
to increased free fatty acid production (45). Saturated fatty acids such as palmitate found to be 
increased in obesity/ T2D has been shown to induce pro-inflammatory cytokines such as TNF-
α,IL-6 and IL-8 (45).  Additionally, saturated fatty acids activate toll like receptor 4 which then 
activate the JNK & IKKβ which activate inflammatory signalling pathway (37). According to 
Ahmad et al, in obese individuals ,long chain fatty acid  including palmitate has been shown to 
synergistically contribute to increased levels of MCP-1 secretion and production when 
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combined with TNF-α (46). It has also been shown in vitro that MCP-1 can be secreted in 
various cells such as monocytes/macrophages and adipocytes when responding to the stimuli 
such as increased levels of TNF-α, free fatty acids and lipopolysaccharides (LPS) (46).This is 
also achieved by the TLR 4 -mediated signalling (45, 46). Moreover, obese individuals has also 
been shown that an interaction between  LPS and TLR4 result in activation of different 
signalling mechanisms including AP1,JNK,MAPKs, ERK1/2 and NF-k B(46). MCP-1 then 
attract the monocytes to the macrophages (12, 47). The monocytes then migrate from the blood 
to the adipose tissue and macrophages where they differentiate into macrophages and secrete 
more cytokines (44, 47). Additionally, the recruited monocytes undergo the uptake of glucose 
to decrease glucose from circulation contributing to a decrease in immune response due to 
decreased in glucose concentration (44). However due to hyperglycaemia there is still 
recruitment of monocytes which correlates with the increase in percentage count of blood 
monocytes at week 12.  
According to literature there is recruitment of eosinophils in T2D patients and secretion of 
cytokines such as IL-13, IL-6 and IL-4, where IL-4 sustains the alternatively activated 
macrophages (48). It is debatable whether the secreted IL-4 is secreted at pre-diabetic state and 
if it also sustains the alternatively activated macrophages at pre-diabetic stage to release more 
pro-inflammatory cytokines. According to Wu et al, eosinophils secrete cytokines such as IL-
6, IL-4 and IL-13 (48) . Moreover the secreted IL-4 and IL-13 sustains alternatively macrophage 
activation of adipose tissue macrophages (48). They also maintain plasma cells in bone marrow 
(14). Therefore, based on the results we can speculate that the eosinophils migrate to the 
inflamed areas such as adipose tissue to sustain alternatively activated macrophages which then 
decreased their concentration in blood. This was further observed in the histology as it showed 
eosinophils embedded in-between the adipocytes. 
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According to literature, inflammatory cytokines  such as CRP, TNF-α and IL-6 are elevated in 
T2D (30, 49). CRP has been shown to be the hepatokine that is associated with obesity  and  a 
potential risk factor for the development of T2D (50). CRP has also been shown to be linked 
with blood pressure and hyperlipidaemia contributing to progression of T2D (50). The results 
of the study show a significant increase in concentration at pre-diabetes implying contribution 
of T2D and cardiovascular complications. However ,TNF-α has been shown to be the key role 
linking obesity and T2D and has also been discovered to be a potent mediator/regulator of 
inflammation (50). According to Ahmad et al, it has also been discovered to play a role in 
inflammation and systemic insulin resistance (50). The results of this study show that there was 
a significant increase of TNF-α concentration at the pre-diabetic stage. TNF- α  has been 
discovered to be increased due to insulin resistance caused by hyperglycaemia and 
hyperinsulinemia in monocytes and macrophages (51). However, the increase in activated 
macrophages have impact on release of nitric oxide by inducible nitric oxide synthase which 
results in the degradation of IRS-1 causing more insulin resistance thus increasing progression 
of pre-diabetes. By inducing adipocyte insulin resistance, TNF- α can also impair glucose 
uptake into adipocytes (52, 53). It also downregulates lipoprotein lipase expression in adipose 
tissue which can contribute to development of hyperlipidaemia which will lead to the 
development of T2D (53). IL-6 is secreted by most immune cells and was significantly 
increased by high-fat high-carbohydrate induced pre-diabetes. This cytokine (TNF- α) is one of 
the downstream target of NF-k B activation which promote a feed forward mechanism of 
inflammation (37, 54).  
Additionally, T2D has been shown to have elevated levels of P-selectin, CD40 ligand and 
fibrinogen due to activation and accumulation of platelets in the damaged endothelium caused 
by oxidative stress and metabolic inflammation (55-57). In this study the increase in P-selectin 
indicated activated platelets and slight increase of CD40L indicate a beginning of the 
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accumulation of platelets in damaged endothelium. According to Linderman et al, in T2D  P-
selectin is secreted by activated platelets and  CD40L confirms firm binding of platelets to the 
damaged endothelium (58). CD40L released further induce expression of pro-inflammatory 
cytokines in the damaged endothelium (58, 59). Furthermore, fibrinogen has been discovered 
to bind to receptors to platelet membrane during  activated platelet aggregation (20, 55). In 
development of atherosclerosis, fibrinogen has been shown to form fibrin and fibrinogen 
degradation products which in turn bind LDL and stimulates cell proliferation (60, 61). 
However, we can speculate that in this study a slight increase in plasma fibrinogen 
concentration may indicate platelet aggregation and early characteristic of atherosclerosis 
development or cardiovascular risk factor. 
2.6. Conclusion 
In conclusion, chronic ingestion of a high-fat high-carbohydrate diet-induces pre-diabetes 
which then triggers an immune response. The immune response involves the recruitment of 
neutrophils, lymphocyte, monocytes, eosinophils and basophils. Immune cells such as 
neutrophils and eosinophils also migrate to inflamed areas such as visceral adipose tissue where 
they are imbedded in-between adipocytes. This then results in secretion of cytokines and 
increased secretion of TNF-α, CRP, CD40L, fibrinogen, P-selectin and IL-6 which possibly 
cause more immune response and inflammation due to activation of kinases that activate NF-k 
B and AP-1. The findings of this study warrant further investigations into the changes in the 
immune system during the development of type 2 diabetes from pre-diabetes in the high-fat 
high carbohydrate diet-induced animal model. 
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Table 1: Glycated haemoglobin concentrations (%) and mean arterial pressure of both non-
diabetic control (NC) in comparison with pre-diabetic group (PD) at the end of the experimental 
period. Values are presented as mean ± SEM.   
 
 Week 20 Week 32 
Groups  NC PD NC PD 
HbA1c (%) 3.8±1.17   6.3±0.36*  4.3±0.26   6.6±0.98*   
MAP (mmHg) 68.7±0.66 98.3±0.44* 72.0±0.96 107.3±0.89* 













Table 2: Plasma lipid profile of both non-diabetic control (NC) in comparison with pre-diabetic 
group (PD) at the end of the experimental period. Values are presented as mean ± SEM. 
 
Groups  TC (mmol/L) TG (mmol/L) HDL (mmol/L) LDL (mmol/L) 
NC 4.04±0.032 1.22±0.031 1.70±0.026 2.40±0.045 
PD 4.43±0.041 3.34±0.210* 0.85±0.012* 5.93±0.076* 
































































Figure 1: Plasma glucose levels at the end of experimental period (fig 1a) and the blood 
triglycerides during the progression of pre-diabetic stage (fig 1b) of non-diabetic control (NC) 
and pre-diabetic group (PD) at the end of experimental period. Values are represented as 
standard error of means (±SEM).    =p<0.05 vs non-diabetic control. 



























Figure 2: Oral glucose tolerance response of non-diabetic control (NC) and pre-diabetic group 
(PD) at the end of experimental period. Values are represented as standard error of means 



































Figure 3: Blood neutrophil percentage count of non-diabetic control (NC) and pre-diabetic 














Figure 4: Photomicrographs illustrating the infiltration of neutrophil and eosinophils (immune 
cells) in adipose tissues due to inflammation in the non-diabetic control (A and C) compared 
with a pre-diabetic group (B and D) where C (cytoplasmic membrane) and N (neutrophil). 






























Figure 5: Blood lymphocytes percentage count of non-diabetic control (NC) and pre-diabetic 




































Figure6: Blood monocyte percentage count of non-diabetic control (NC) and pre-diabetic 




























Figure 7: Blood eosinophils percentage count of non-diabetic control (NC) and pre-diabetic 































Figure 8: Blood basophils percentage count of non-diabetic control (NC) and pre-diabetic 
group (PD). Values are represented as standard error of means (±SEM).   =p<0.05 vs non-


























































































































Figure 9: Inflammatory markers concentrations of non-diabetic control (NC) and pre-diabetic 
group (PD) after 12 weeks experimental period with TNF-α (a), IL-6 (b), CRP (c), fibrinogen 
(d), CD40-L (e) and P-selectin (f). Values are represented as standard error of means (±SEM).            















CHAPTER 3: SYNTHESIS 
Chronic ingestion of a high-fat high carbohydrate (HFHC) diet has been shown to induce pre-
diabetes (1). Prediabetes has been shown to precede the onset of T2D. The animals in this study 
developed prediabetes after ingesting a HFHC diet for 20 weeks. This was shown by the 
increase in fasting plasma glucose levels and elevated levels of glycated haemoglobin. The 
animals also further displayed impaired glucose tolerance over the 2h OGT. Following a further 
12 weeks of ingesting the HFHC diet, the plasma levels of glycated haemoglobin indicated that 
the animals had developed T2D. This was accompanied by a dysregulated lipid profile as shown 
by an increase in triglycerides, LDL and a decrease in HDL indicating hypercholesterolemia. 
T2D has been shown to have increased levels of triglycerides indicating dyslipidaemia due to 
accumulation of fats (2). T2D adipose tissue has been discovered to be one of the inflamed 
areas due to accumulation of fats which also cause insulin resistance (3). In this study, during 
the progression of pre-diabetes to T2D an increase of triglycerides levels every fourth week 
was observed. Moreover, in T2D accumulation of fats such as saturated fatty acids caused 
lipotoxicity which triggered an immune response (4). Additionally the elevated blood glucose 
levels over the experimental period may have triggered an immune response (5). 
During immune response in T2D there is an increase in production of neutrophils which are the 
first immune cells to be recruited into an inflamed area such as in adipose tissue, damaged 
endothelium (6-9). An increase in circulating neutrophils concentration during progression of 
pre-diabetes stage indicated increased production from immune response. However, as the stage 
progressed there was a gradual decrease in neutrophils, and they were further observed in the 
histology of visceral adipose tissue dissected from the abdominal area of the rats. 
T2D triggers an immune response resulting in an increase in lymphocytes concentrations (8, 
10). B-cells mature to plasma cells and secrete antibodies such as IgE ,IgG (11). Additionally, 
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T-cells detect an antigen and secrete cytokines such as IL-6 (8). An increased in lymphocytes 
during progression of pre-diabetes stage (week 12) further indicated glucotoxicity. Monocytes 
play a huge role in T2D during immune response by facilitating the uptake of circulating 
glucose from the blood (10). Monocytes has been shown to have glucose transporters for 
glucose uptake to decrease it from circulation (10). Additionally, in T2D monocytes mature 
into macrophages and secrete pro-inflammatory cytokines such as TNF-α for inflammation (8, 
10, 12). Furthermore, in T2D monocytes migrate to the intima due to dysfunctional endothelium 
and differentiate into macrophages which allow accumulation of LDL into foam cells 
contributing to atherosclerosis (13, 14). In this study there was an increase also an increase in 
monocytes at week 12. However, an increase at week 12 indicated that there was a certain 
number of monocytes that had matured to macrophages and the increasing amount was due to 
glucotoxicity causing more production of monocytes for the uptake of circulating glucose trying 
to decrease glucose to a normal level. 
In T2D IgE antibodies bind to basophils that are produced during immune response since 
basophils display an IgE binding receptor to bind and activate the basophils (11, 15). This 
binding then activates basophils to secrete pro-inflammatory cytokines for inflammation which 
contributes to progression of T2D. An increase in basophil percentage count indicated the 
immune response and further secretion of cytokines for inflammation. The eosinophils has been 
shown to secrete cytokines for inflammation in the inflamed area in T2D (15, 16). Eosinophil 
are also produced due to hyperglycaemia in T2D (16). However they are then recruited to 
inflamed areas such as adipose tissue (16). In this study eosinophil blood percentage count 
occurred at week 8. However, there was a decrease in circulating eosinophil percentage count, 
indicating their recruitment to an inflamed area as it was further observed in a histology of 
visceral adipose tissue disserted from the abdominal area of the rat. 
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T2D abnormalities such as atherosclerosis has been shown to be due to inflammatory 
complications such as an increase in P-selectin and CD40L due to oxidative stress that damage 
the endothelium (17-19). Additionally T2D hepatocytes produce CRP which has also been 
shown to be elevated and also contributing to increased arterial pressure resulting in 
hypertension (20, 21). CRP, CD40L and P-selectin has been shown to be elevated at pre-
diabetes stage.  Additionally, an increased in mean arterial pressure was also observed in this 
study. T2D has also been shown do have elevated levels of inflammatory markers such as IL-6 
and TNF-α (12, 21, 22). Hyperfibrinogenaemia is also another characteristic of T2D that 
contribute to cardiovascular abnormalities (23, 24). Fibrinogen, IL-6 and TNF-α contributing 
to inflammation and onset of T2D. In T2D it has been shown that oxidative stress, 
hyperglycaemia, hyperlipidaemia and cytokines activate NF-KB and AP-1 contributing to more 
insulin resistance and inflammation.  
CONCLUSION 
Taken together, the results of this study show that chronic consumption of a high fat high 
carbohydrate diet leads to the development of prediabetes which, if continued, later develops 
into type 2 diabetes. The results also suggest that there is of immune activation during the 
prediabetes stage as evidenced by changes in concentration of immune cells at pre-diabetic 
stage and the upregulation of inflammatory markers contributing to inflammation and onset of 
T2D.  
SHORTFALLS FUTURE STUDIES  
The expression of the cytokines could not be measured in the inflamed areas such as in adipose 
tissue and the only targeted inflamed area was visceral adipose tissue. For future studies, 
expression of the cytokines in inflamed areas is recommended and histology of other inflamed 
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Think about the last time you searched online for research that was relevant to your field. 
You’ll have put in certain keywords. Now think about your article and how someone might 
find it. What search terms might they use? You want your article to come up, so make your 
title specific and try to include words that readers might be searching for. Try to make it 
understandable to a reader from outside your field and, where possible, avoid abbreviations, 
formulae, and numbers. 
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Higher Education Research & Development accepts the following types of article: original 
articles. 
Peer Review 
Taylor & Francis is committed to peer-review integrity and upholding the highest standards of 
review. Once your paper has been assessed for suitability by the editor, it will then be double 
blind peer reviewed by independent, anonymous expert referees. Find out more about what to 
expect during peer review and read our guidance on publishing ethics. 
Preparing Your Paper 
Structure 
Your paper should be compiled in the following order: title page; abstract; keywords; main 
text introduction, materials and methods, results, discussion; acknowledgments; declaration of 
interest statement; references; appendices (as appropriate); table(s) with caption(s) (on 
individual pages); figures; figure captions (as a list). 
Word Limits 
Please include a word count for your paper. 
A typical paper for this journal should be between 5000 and 7000 words, inclusive of the 
abstract, tables, references, figure captions, footnotes, endnotes. 
Style Guidelines 
Please refer to these quick style guidelines when preparing your paper, rather than any 
published articles or a sample copy. 
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Please use spelling style consistently throughout your manuscript. 
Please note that long quotations should be indented without quotation marks. 
Formatting and Templates 
Papers may be submitted in Word format. Figures should be saved separately from the text. 
To assist you in preparing your paper, we provide formatting template(s). 
Word templates are available for this journal. Please save the template to your hard drive, 
ready for use. 
If you are not able to use the template via the links (or if you have any other template queries) 
please contact us  here. 
References 
Please use this reference guide when preparing your paper. 
Checklist: What to Include 
1. Author details. All authors of a manuscript should include their full name and affiliation on the 
cover page of the manuscript. Where available, please also include ORCiDs and social media 
handles (Facebook, Twitter or LinkedIn). One author will need to be identified as the 
corresponding author, with their email address normally displayed in the article PDF 
(depending on the journal) and the online article. Authors’ affiliations are the affiliations where 
the research was conducted. If any of the named co-authors moves affiliation during the peer-
review process, the new affiliation can be given as a footnote. Please note that no changes to 
affiliation can be made after your paper is accepted. Read more on authorship. 
2. An unstructured abstract of no more than 300 words. Read tips on writing your abstract. 
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3. You can opt to include a video abstract with your article. Find out how these can help your 
work reach a wider audience, and what to think about when filming. 
4. Read making your article more discoverable, including information on choosing a title and 
search engine optimization. 
5. Funding details. Please supply all details required by your funding and grant-awarding bodies 
as follows:  
For single agency grants  
This work was supported by the [Funding Agency] under Grant [number xxxx].  
For multiple agency grants  
This work was supported by the [Funding Agency #1] under Grant [number xxxx]; [Funding 
Agency #2] under Grant [number xxxx]; and [Funding Agency #3] under Grant [number 
xxxx]. 
6. Disclosure statement. This is to acknowledge any financial interest or benefit that has arisen 
from the direct applications of your research. Further guidance on what is a conflict of interest 
and how to disclose it. 
7. Data Availability Statement: If there is a data set associated with the paper, please provide 
information about where the data supporting the results or analyses presented in the paper can 
be found. Where applicable, this should include the hyperlink, DOI or other persistent identifier 
associated with the data set(s). Templates are also available to support authors. 
8. Data deposition. If you choose to share or make the data underlying the study open, please 
deposit your data in a recognized data repository prior to or at the time of submission. You will 
be asked to provide the DOI, pre-reserved DOI, or other persistent identifier for the data set. 
9. Geolocation information. Submitting a geolocation information section, as a separate paragraph 
before your acknowledgements, means we can index your paper’s study area accurately in 
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JournalMap’s geographic literature database and make your article more discoverable to 
others. More information. 
10. Supplemental online material. Supplemental material can be a video, dataset, fileset, sound file 
or anything which supports (and is pertinent to) your paper. We publish supplemental material 
online via Figshare. Find out more about supplemental material and how to submit it with your 
article. 
11. Figures. Figures should be high quality (1200 dpi for line art, 600 dpi for grayscale and 300 dpi 
for colour). Figures should be saved as TIFF, PostScript or EPS files. 
12. Tables. Tables should present new information rather than duplicating what is in the text. 
Readers should be able to interpret the table without reference to the text. Please supply editable 
files. 
13. Equations. If you are submitting your manuscript as a Word document, please ensure that 
equations are editable. More information about mathematical symbols and equations. 
14. Units. Please use SI units (non-italicized). 
Book reviews 
Book reviews of up to 1200-1500 words are invited. Reviews should be of recently published 
books dealing with any aspect of higher education that the reviewer considers to be inspiring 
or to have significant implications for future policy, research and/or practice in higher 
education. Do not use ScholarOne to submit your review. Reviews are emailed to the Review 
Editor Dr Deanne Gannaway at d.gannaway@uq.edu.au. 
Review Guidelines 
The following identify some of the general features common to good book reviews that we 
are seeking. The review should: 
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         convey the content of the book, the author's approach to the subject, and the 
author's conclusions/viewpoint/argument (the warrant of the book), using an integrated 
approach rather than chapter-by-chapter listing of themes. 
         place the book in the context of its field and give a sense of the book's 
significance. 
         present a balanced analysis of the book's strengths and weaknesses and illustrate 
those points with examples. 
         be scholarly yet written in language accessible to a generalist audience. We 
assume that our readers are knowledgeable about education but may not be specialists 
in a particular field. 
         be written in a clear and lively style that is both interesting and engaging. 
Using Third-Party Material in your Paper 
You must obtain the necessary permission to reuse third-party material in your article. The 
use of short extracts of text and some other types of material is usually permitted, on a limited 
basis, for the purposes of criticism and review without securing formal permission. If you 
wish to include any material in your paper for which you do not hold copyright, and which is 
not covered by this informal agreement, you will need to obtain written permission from the 
copyright owner prior to submission. More information on requesting permission to reproduce 
work(s) under copyright. 
Submitting Your Paper 
Please note that Higher Education Research & Development uses Cross ref™ to screen papers 
for unoriginal material. By submitting your paper to Higher Education Research & 
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Development you are agreeing to originality checks during the peer-review and production 
processes. 
On acceptance, we recommend that you keep a copy of your Accepted Manuscript. Find out 
more about sharing your work. 
Publication Charges 
There are no submission fees, publication fees or page charges for this journal.   
Colour figures will be reproduced in colour in your online article free of charge. If it is 
necessary for the figures to be reproduced in colour in the print version, a charge will apply. 
Charges for colour figures in print are £250 per figure ($395 US Dollars; $385 Australian 
Dollars; €315). For more than 4 colour figures, figures 5 and above will be charged at £50 per 
figure ($80 US Dollars; $75 Australian Dollars; €63). Depending on your location, these 
charges may be subject to local taxes. 
Copyright Options 
Copyright allows you to protect your original material and stop others from using your work 
without your permission. Taylor & Francis offers a number of different license and reuse 
options, including Creative Commons licenses when publishing open access. Read more on 
publishing agreements. 
Complying with Funding Agencies 
We will deposit all National Institutes of Health or Wellcome Trust-funded papers into 
PubMedCentral on behalf of authors, meeting the requirements of their respective open access 
policies. If this applies to you, please tell our production team when you receive your article 
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proofs, so we can do this for you. Check funders’ open access policy mandates here. Find out 
more about sharing your work. 
Open Access 
This journal gives authors the option to publish open access via our Open Select publishing 
program, making it free to access online immediately on publication. Many funders mandate 
publishing your research open access; you can check open access funder policies and 
mandates here. 
Taylor & Francis Open Select gives you, your institution or funder the option of paying an 
article publishing charge (APC) to make an article open access. Please 
contact openaccess@tandf.co.uk if you would like to find out more, or go to our Author 
Services website. 
For more information on license options, embargo periods and APCs for this journal please 
go here. 
My Authored Works 
On publication, you will be able to view, download and check your article’s metrics 
(downloads, citations and Altmetric data) via My Authored Works on Taylor & Francis 
Online. This is where you can access every article you have published with us, as well as 
your free eprints link, so you can quickly and easily share your work with friends and 
colleagues. 
We are committed to promoting and increasing the visibility of your article. Here are some 




You will be sent a link to order article reprints via your account in our production system. For 
enquiries about reprints, please contact the Taylor & Francis Author Services team 
at reprints@tandf.co.uk. You can also order print copies of the journal issue in which your 
article appears. 
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Should you have any queries, please visit our Author Services website or contact us at here. 
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